Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/80594
| Title: | Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation | Authors: | Li, XX Lu, XY Zhang, SJ Chiu, AP Lo, LH Largaespada, DA Chen, QB Keng, VW |
Issue Date: | Mar-2019 | Source: | Biomedicine and pharmacotherapy, Mar. 2019, v. 111, p. 68-75 | Abstract: | Non-alcoholic fatty liver disease (NAFLD) is becoming an epidemic disease in adults and children worldwide. Importantly, there are currently no approved treatments available for NAFLD. This study aims to investigate the potential applications of sodium tanshinone IIA sulfonate (STS) on improving the NAFLD condition using both in vitro and in vivo approaches. The results showed that STS markedly inhibited lipid accumulation in oleic acid (OA) and palmitic acid (PA) treated HepG2 and primary immortalized human hepatic (PIH) cells. STS suppressed lipogenesis by inhibiting expression of sterol regulatory element binding transcription factor 1 (SREBF1), fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In addition, STS reduced inflammation in cells treated with OA-PA, shown by decreased transcriptional levels of tumor necrosis factor (TNF), transforming growth factor beta 1 (TGFB1) and interleukin 1 beta (IL1B). Consistently, protective effects on hepatic steatosis in db/db mice were observed after STS administration, demonstrated by decreased lipid accumulation in mouse hepatocytes. This protective effect might be associated with STS induced activation of sirtuin 1 (SIRT1)/protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1) pathways. Our findings suggest a potential therapeutic role for STS in the treatment of NAFLD. | Keywords: | NAFLD PRKAA1 SIRT1 Sodium tanshinone IIA sulfonate |
Publisher: | Elsevier Masson | Journal: | Biomedicine and pharmacotherapy | EISSN: | 0753-3322 | DOI: | 10.1016/j.biopha.2018.12.019 | Rights: | © 2018 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/). The following publication: Li, X. X., Lu, X. Y., Zhang, S. J., Chiu, A. P., Lo, L. H., Largaespada, D. A., ... & Keng, V. W. (2019). Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomedicine & Pharmacotherapy, 111, 68-75 is available at https://doi.org/10.1016/j.biopha.2018.12.019 |
| Appears in Collections: | Journal/Magazine Article |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Li_Sodium_tanshinone_IIA.pdf | 2.88 MB | Adobe PDF | View/Open |
Access
View full-text via PolyU eLinks 
Page views
121
Last Week
2
2
Last month
Citations as of Jun 11, 2023
Downloads
145
Citations as of Jun 11, 2023
SCOPUSTM
Citations
24
Citations as of Jun 8, 2023
WEB OF SCIENCETM
Citations
22
Citations as of Jun 8, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.